Enanta Pharmaceuticals INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Enanta Pharmaceuticals, Inc. reported its fiscal year 2025 results, highlighting progress in its RSV and immunology pipelines, alongside a decrease in HCV royalty revenue and continued operating losses.
NASDAQ
Enanta Pharmaceuticals' 10-K filing highlights its ongoing clinical programs in RSV and preclinical efforts in immunology, while also detailing its financial performance and reliance on AbbVie royalties.